Study tracks lipid transfer from neighboring cells in pancreatic tumors
Experiments suggest that surrounding support cells help pancreatic cancer cells obtain lipids, with the protein ANO6 involved in the exchange. Blocking this pathway reduced tumor growth and immune suppression in preclinical work. The peer-reviewed findings identify a possible research target, while cell and mouse results leave effectiveness and safety in patients unresolved.
Science··Night
Support cells supply tumor resources
Cells surrounding pancreatic tumors can participate actively in the cancer’s supply of fats. Peer-reviewed experiments published in Nature Cancer link this exchange to ANO6, a protein acting in fibroblasts, the support cells within the tumor’s dense connective tissue. Laboratory and mouse findings connect reduced ANO6 activity with slower tumor growth and less immune suppression. They identify a possible research target rather than an established treatment for patients.[1], [2]
Dense tissue shapes the nutrient exchange
Pancreatic tumors develop amid dense tissue with few functional blood vessels, creating a difficult nutrient environment. The experiments followed blood-derived lipids entering fibroblasts before reaching cancer cells in contact with them. These lipids help build cell membranes and support growth. The exchange involves acquiring small pieces of a neighbouring cell’s membrane. Cancer cells also retain other routes for obtaining or producing the fats they need.[1]
The cancer studied is pancreatic ductal adenocarcinoma, the most common pancreatic cancer. Researchers led by Fox Chase Cancer Center examined the role of surrounding fibroblasts rather than treating them as passive tissue. Their findings place these cells between the bloodstream and nearby cancer cells in the movement of resources. Dependence on this route can vary with the tumor subtype and the nutrients available, alongside the cells’ other lipid sources.[1], [2]
Immune effects accompany the growth findings
The study also observed suppressive changes in immune cells interacting with fibroblasts. Interpreting the tumor-growth result remains complicated because reducing ANO6 changed broader support-cell behaviour, and the tested drugs can act on additional targets. Human tumor samples linked higher ANO6 with poorer survival, an observational association. Whether a selective intervention brings clinical benefit, and how safely it could be used in people, require separate investigation.[1]
Cytotoxic T cells are immune cells that can recognize and kill cancer cells. The work links their contacts with fibroblasts to cholesterol accumulation and impaired activity in the tumor environment. Reduced ANO6 activity accompanied lower cholesterol accumulation in tumor-infiltrating T cells and improved activity markers. The findings connect two functions of the surrounding tissue—support for cancer nutrition and interference with immune responses—within the tested laboratory and animal systems.[1], [2]
